Chemical Namelemborexant
Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassReceptor antagonists
CompanyEisai Inc.
Approval Year2019


  • Dayvigo is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dayvigo (lemborexant) Prescribing Information2020Eisai
Document TitleYearSource
Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.2020Journal of Psychiatric Research
Pharmacotherapies for sleep disturbances in dementia.2020Cochrane Database of Systematic Reviews